Company news

Valion Bio, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Valion Bio Advancing Entolimod into U.S. Government-Funded Therapeutic Efficacy Study Following Positive Safety Results

October 30, 2026

Valion Bio Announces Positive Safety Results From U.S. Government-Funded Entolimod Study, Paving Way For Therapeutic Efficacy Evaluation

October 28, 2026

Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options

October 26, 2026

Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value

October 21, 2026

Valion Bio's Next-Generation NMR Partnership with LarmorBio Delivers Initial Feasibility Milestone

October 15, 2026

With Section 232 Tariffs Reshaping Biotech, Valion Bio's Velocity Bioworks Capitalizes on Domestic CDMO Surge

October 14, 2026

Valion Appoints Life Sciences Veteran Dean Zikria as Interim CEO and Announces Board Leadership Transitions

September 23, 2026

Valion Bio Regains Compliance with NASDAQ Minimum Bid Price Listing Rule

September 22, 2026

Valion Bio Announces Reverse Stock Split

August 27, 2026

Valion Bio Announces U.S. Government-Funded Entolimod Studies Targeting Lethal Radiation-Induced GI Injury

August 12, 2026

Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway

July 22, 2026

Valion Bio Advances Integrated Biodefense and Immunology Platform Through Continued Government Engagement, Domestic Manufacturing and Oncology Expansion

July 14, 2026

AFRRI/NIAID Designs Proprietary PBI-BM2.5 Protocol to Evaluate Valion Bio's (NASDAQ: VBIO) Entolimod as the First and Only Treatment for GI-ARS

June 25, 2026

Valion Bio (NASDAQ: VBIO) Confirms U.S. House Armed Services Committee Initiative to Address Urgent Need for Radiation /Nuclear Countermeasures

June 11, 2026

Valion Bio briefs senior Department of War and BARDA officials in joint engagement on Entolimod for acute radiation syndrome

May 19, 2026

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR Platform

May 15, 2026

Valion Bio's Velocity Bioworks Secures Exclusive Commercial License to LarmorBio's BioScan-NMR™ Platform

May 14, 2026

Valion Bio reports first quarter 2026 financial results

May 14, 2026

Valion Bio to Report First Quarter 2026 Financial Results on May 14, 2026

May 11, 2026

Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimod™

May 6, 2026

Valion Bio receives first FDA-precedent study protocol from NIAID for Entolimod™; federal agency to fully fund BLA-enabling in vivo program and co-navigate FDA submission

May 5, 2026

Valion Bio Appoints Melinda Lackey as General Counsel

May 4, 2026

Valion Bio briefs Pentagon leadership on Entolimod™ for acute radiation syndrome

April 28, 2026

Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model

April 24, 2026

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 10 decks. Every deck is listed under its year.